PCE

Optimizing Immune Checkpoint Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer

Episode Summary

Learn from a leading expert about optimizing immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) including individualizing therapy decisions and managing adverse events.

Episode Notes

In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.

Topics include:

• Currently approved ICIs
• Role of biomarker and PD-L1 testing in advanced NSCLC
• Strategies to individualize ICI treatment for patients with advanced NSCLC
• Strategies for identifying and managing immune-related adverse events in patients treated with ICI

Presenter:
Sandip P. Patel, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California – San Diego
La Jolla, California 

Link to full program:
https://bit.ly/39vuCHC